



Prof.ssa Vincenza Dolo

Via Vetoio- Coppito 2-67100 L'Aquila
Tel: +390862433665; Fax: +39086243785

vincenza.dolo@univaq.it ; www.patologiaclinica.it

Profilo Accademico

- Professore Associato di Patologia Clinica
- Direttore della Scuola di Specializzazione in Patologia Clinica
- Presidente del Corso di Laurea in Scienze delle Professioni Sanitarie Tecnico-Diagnostiche
- Responsabile del Laboratorio di Patologia Clinica presso il Dipartimento di Scienze della Salute

Carriera Accademica

- Laurea in Scienze Biologiche summa cum laude
- PhD in Biologia Cellulare e dello Sviluppo
- Specializzazione in Patologia Clinica
- Assistente Tecnico presso il Dipartimento di Medicina Sperimentale, Univ. Dell'Aquila 2000
- Ricercatore Universitario di Patologia Clinica, Facoltà di Medicina e Chirurgia, Univ. dell'Aquila 2002
- Professore Associato di Patologia Clinica, facoltà di Medicina e Chirurgia, Univ. dell'Aquila 2006 ad oggi

Formazione professionale nazionale ed internazionale

- Formazione scientifica: Dipartimento di Genetica dell'Università di Torino per perfezionare tecniche di produzione di anticorpi monoclonali 1991
- Borsa di studio dal Gruppo di Cooperazione in Immunologia presso la Divisione di Oncologia Sperimentale E dell'Istituto nazionale Tumori di Milano 1993
- Formazione scientifica presso la Divisione di Microscopia Elettronica del Dipartimento di Patologia e Medicina Sperimentale, Univ. La Sapienza Roma 1994-1995
- Visiting scientist presso il Center for Cancer Research and Transplantation Biology, Children's National Medical Center, Washington DC 1998
- Visiting scientist with Erasmus Programme presso il Department of Immunology and Gnotobiology, Institute of Microbiology, Academy of Sciences of the Czech Republic, Praga 2011

Partecipazione a Collegi di Dottorato

- Collegio dei Docenti del Dottorato in “Epidemiologia e Diagnostica Avanzata in Patologia Comparata” Ciclo XX presso L’Univesità degli Studi di Teramo
- Collegio dei Docenti del Dottorato in “Biotecnologie” Ciclo XXI presso l’Università degli Studi di L’Aquila.
- Collegio dei Docenti del Dottorato in Medicina Traslazionale: metodologie molecolari diagnostiche e terapeutiche applicate alle scienze medico-chirurgiche e psicocomportamentali XXV-XXVI ciclo

Associazioni Scientifiche

- Società Italiana di Medicina di Laboratorio (SIMEL)
- Associazione Italiana Patologi Clinica (AIPAC)
- Società Italiana di Microscopia Elettronica
- Metastasis Research Society
- European Association for Cancer Research
- Società Italiana di Cancerologia

Principali linee di ricerca

- Studi morfodinamici della membrana plasmatica in situazioni pato/fisiologiche con metodiche di microscopia elettronica
- Espressione e localizzazione di molecole glicosfingolipidiche sulla membrana plasmatica e loro coinvolgimento in patologie degenerative
- Studio di nuove metodologie per la valutazione del rischio tossicologico derivante dall’esposizione di sostanze e metodi doping nelle attività sportive
- Studio dei meccanismi molecolari coinvolti nella farmaco-resistenza
- Studio dei meccanismi molecolari coinvolti nell’angiogenesi tumorale
- Studio sugli effetti biologici del gel piastrinico su differenti tipi cellulari

Publications

1. An acid extract from dissociation medium of sea urchin embryos, induces mesenchyme differentiation. Dolo V, Forti C, Dell'Utri S, Ghersi G, Vittorelli ML. Cell Biol Int Rep. 1992 Jun;16(6):517-32.
2. Differential expression and function of cadherin-like proteins in the sea urchin embryo. Ghersi G, Salamone M, Dolo V, Levi G, Vittorelli ML. Mech Dev. 1993 Apr;41(1):47-55.
3. Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. Dolo V, Ginestra A, Ghersi G, Nagase H, Vittorelli ML. J Submicrosc Cytol Pathol. 1994 Apr;26(2):173-80.
4. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Dolo V, Adobati E, Canevari S, Picone MA, Vittorelli ML. Clin Exp Metastasis. 1995 Jul;13(4):277-86.
5. Inhibitory effects of vesicles shed by human breast carcinoma cells on lymphocyte 3H-thymidine incorporation, are neutralised by anti TGF-beta antibodies. Dolo V, Pizzurro P, Ginestra A, Vittorelli ML. J Submicrosc Cytol Pathol. 1995 Oct;27(4):535-41.
6. Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Dolo V, Ginestra A, Violini S, Miotti S, Festuccia C, Miceli D, Migliavacca M, Rinaudo C, Romano FM, Brisdelli F, Canevari S, Pavan A, Vittorelli ML. Oncol Res. 1997;9(3):129-38.
7. Evidence for the existence of ganglioside-enriched plasma membrane domains in human peripheral lymphocytes. Sorice M, Parolini I, Sansolini T, Garofalo T, Dolo V, Sargiacomo M, Tai T, Peschle C, Torrissi MR, Pavan A. J Lipid Res. 1997 May;38(5):969-80.
8. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, Vittorelli ML. J Biol Chem. 1997 Jul 4;272(27):17216-22.
9. Modulation of vesicle shedding in 8701 BC human breast carcinoma cells. Cassarà D, Ginestra A, Dolo V, Miele M, Caruso G, Lucania G, Vittorelli ML. J Submicrosc Cytol Pathol. 1998 Jan;30(1):45-53.
10. Thermal behavior of human melanoma cell line in vitro and enhancement of hyperthermic response by bupivacaine. Bruno T, Gentile FP, Di Padova M, Antonucci E, Rubiu O, Dolo V, Pavan A, Floridi A. Oncol Res. 1998;10(3):143-50.
11. Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Dolo V, Ginestra A, Cassarà D, Violini S, Lucania G, Torrissi MR, Nagase H, Canevari S, Pavan A, Vittorelli ML. Cancer Res. 1998 Oct 1;58(19):4468-74.
12. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M. Clin Exp Metastasis. 1998 Aug;16(6):513-28.
13. Morphological analysis of the interaction of charged surfactant vesicles (SVs) with human cultured cells. Carafa M, Lucania G, Marchei E, Dolo V, Giammatteo M, Torrissi MR, Santucci E, Pavan A. Biotech Histochem. 1999 Mar;74(2):77-84.
14. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, Pavan A. Clin Exp Metastasis. 1999 Mar;17(2):131-40.

15. Shed membrane vesicles and selective localization of gelatinases and MMP-9/TIMP-1 complexes. Dolo V, Ginestra A, Cassarà D, Gherzi G, Nagase H, Vittorelli ML. *Ann N Y Acad Sci.* 1999 Jun 30;878:497-9. No abstract available.
16. Glycosphingolipid domains on cell plasma membrane. Sorice M, Garofalo T, Misasi R, Dolo V, Lucania G, Sansolini T, Parolini I, Sargiacomo M, Torrisi MR, Pavan A. *Biosci Rep* 1999 Jun;19(3):197-208.
17. Membrane vesicles in ovarian cancer fluids: a new potential marker. Ginestra A, Miceli D, Dolo V, Romano FM, Vittorelli ML. *Anticancer Res.* 1999 Jul-Aug;19(4C):3439-45.
18. Expression of GM3 microdomains on the surfaces of murine fibroblasts correlates with inhibition of cell proliferation. Visco V, Lucania G, Sansolini T, Dolo V, Garofalo T, Sorice M, Frati L, Torrisi MR, Pavan A. *Histochem Cell Biol.* 2000 Jan;113(1):43-50.
19. Evidence that ganglioside enriched domains are distinct from caveolae in MDCK II and human fibroblast cells in culture. Chigorno V, Palestini P, Sciannamblo M, Dolo V, Pavan A, Tettamanti G, Sonnino S. *Eur J Biochem.* 2000 Jul;267(13):4187-97.
20. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Dolo V, Li R, Dillinger M, Flati S, Manela J, Taylor BJ, Pavan A, Ladisch S. *Biochim Biophys Acta.* 2000 Jul 19;1486(2-3):265-74.
21. Specific neurons of brain cortex and cerebellum are PIPPin positive. Nastasi T, Muzi P, Beccari S, Bellafiore M, Dolo V, Bologna M, Cestelli A, Di Liegro I. *Neuroreport.* 2000 Jul 14;11(10):2233-6.
22. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S. *Oncogene.* 2000 Sep 28;19(41):4754-63.
23. Association between GM3 and CD4-Ick complex in human peripheral blood lymphocytes. Sorice M, Garofalo T, Misasi R, Longo A, Mikulak J, Dolo V, Pontieri GM, Pavan A. *Glycoconj J.* 2000 Mar-Apr;17(3 - 4):247-52.
24. New approaches to the study of sphingolipid enriched membrane domains: the use of electron microscopic autoradiography to reveal metabolically tritium labeled sphingolipids in cell cultures. Dolo V, D'Ascenzo S, Sorice M, Pavan A, Sciannamblo M, Prinetti A, Chigorno V, Tettamanti G, Sonnino S. *Glycoconj J.* 2000 Mar-Apr;17(3 -4):261-8.
25. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V, Pavan A. *Clin Exp Metastasis.* 2000;18(2):163-70.
26. Evidence for cell surface association between CXCR4 and ganglioside GM3 after gp120 binding in SupT1 lymphoblastoid cells. Sorice M, Garofalo T, Misasi R, Longo A, Mattei V, Sale P, Dolo V, Gradini R, Pavan A. *FEBS Lett.* 2001 Sep 28;506(1):55-60.
27. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. *Am J Pathol.* 2002 Feb;160(2):673-80.
28. Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA I: a(1)H NMR study. Ferretti A, D'Ascenzo S, Knijn A, Iorio E, Dolo V, Pavan A, Podo F. *Br J Cancer.* 2002 Apr 8;86(7):1180-7.
29. Association of cellular prion protein with gangliosides in plasma membrane microdomains of neural and lymphocytic cells. Mattei V, Garofalo T, Misasi R, Gizzi C, Mascellino MT, Dolo V, Pontieri GM, Sorice M, Pavan A. *Neurochem Res.* 2002 Aug;27(7-8):743-9.
30. Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. Taverna S, Gherzi G, Ginestra A, Rigogliuso S, Pecorella S, Alaimo G, Saladino F, Dolo V, Dell'Era P, Pavan A, Pizzolanti G, Mignatti P, Presta M, Vittorelli ML. *J Biol Chem.* 2003 Dec 19;278(51):51911-9.

31. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. Violini S, D'Ascenzo S, Bagnoli M, Millimaggi D, Miotti S, Canevari S, Pavan A, Dolo V. J Exp Clin Cancer Res. 2004 Mar;23(1):83-91.
32. Intrafollicular expression of matrix metalloproteinases and their inhibitors in normally ovulating women compared with patients undergoing in vitro fertilization treatment. D'Ascenzo S, Giusti I, Millimaggi D, Marci R, Tatone C, Cardigno Colonna R, Moscarini M, Pavan A, Dolo V, Caserta D. Eur J Endocrinol. 2004 Jul;151(1):87-91.
33. Shedding of membrane vesicles by tumor and endothelial cells. Dolo V, D'Ascenzo S, Giusti I, Millimaggi D, Taraboletti G, Pavan A. Ital J Anat Embryol. 2005;110(2 Suppl 1):127-33.
34. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. Reprod Biomed Online. 2005 Aug;11(2):189-93.
35. Alterations of choline phospholipid metabolism in ovarian tumor progression. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Cancer Res. 2005 Oct 15;65(20):9369-76.
36. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Specia S, Angelucci A, Dolo V, Vicentini C, Bologna M. Endocr Relat Cancer. 2005 Dec;12(4):983-98.
37. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V. Biochem J. 2006 Apr 15;395(2):311-8.
38. Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Millimaggi D, Festuccia C, Angelucci A, D'Ascenzo S, Rucci N, Flati S, Bologna M, Teti A, Pavan A, Dolo V. Int J Oncol. 2006 Apr;28(4):909-14.
39. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, Dolo V. Neoplasia. 2006 Feb;8(2):96-103.
40. Serum CA125 level modifications in women undergoing repeated IVF cycles. Caserta D, Marci R, Tatone C, Dolo V, Di Roma E, Fazi A, Moscarini M. Eur J Gynaecol Oncol. 2006;27(4):353-5.
41. Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G, Bernardini S. Anticancer Drugs. 2006 Nov;17(10):1141-50.
42. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Festuccia C, Muzi P, Gravina GL, Millimaggi D, Specia S, Dolo V, Ricevuto E, Vicentini C, Bologna M. Int J Oncol. 2007 Jan;30(1):193-200.
43. Detrimental effects of anabolic steroids on human endothelial cells. D'Ascenzo S, Millimaggi D, Di Massimo C, Saccani-Jotti G, Botrè F, Carta G, Tozzi-Ciancarelli MG, Pavan A, Dolo V. Toxicol Lett. 2007 Mar 8;169(2):129-36.
44. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V. Neoplasia. 2007 Apr;9(4):349-57.
45. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S,

Marrelli A, Dolo V, Pavan A, Saccardi R, Tyndall A, Giacomelli R, Cerinic MM. Arthritis Rheum. 2007 Jun;56(6):1994-2004.

46. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiproliferative therapy in prostate carcinoma. Angelucci A, Muzi P, Cristiano L, Millimaggi D, Cimini A, Dolo V, Miano R, Vicentini C, Cerù MP, Bologna M. Prostate. 2008 May 1;68(6):588-98.

47. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M. Prostate. 2008 May 15;68(7):793-801.

48. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M. Prostate. 2008 Jun 15;68(9):965-74.

49. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Giusti I, D'Ascenzo S, Millimaggi D, Tarabozetti G, Carta G, Franceschini N, Pavan A, Dolo V. Neoplasia. 2008 May;10(5):481-8.

50. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M. Int J Oncol. 2008 Aug;33(2):381-8.

51. Platelet gel-released supernatant modulates the angiogenic capability of human endothelial cells. Rugghetti A, Giusti I, D'Ascenzo S, Leocata P, Carta G, Pavan A, Dell'Orso L, Dolo V. Blood Transfus. 2008 Jan;6(1):12-7.

52. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F. Cancer Res. 2008 Aug 15;68(16):6541-9.

53. Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Ficorella C, Ricevuto E, Bologna M. Prostate. 2009 Mar 1;69(4):337-45.

54. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M. Endocr Relat Cancer. 2009 Jun;16(2):401-13.

55. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Giusti I, Rugghetti A, D'Ascenzo S, Millimaggi D, Pavan A, Dell'Orso L, Dolo V. Transfusion. 2009 Apr;49(4):771-8.

56. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels. Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, Bologna M. Urology. 2009 Aug;74(2):452-7.

57. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Festuccia C, Gravina GL, Biordi L, D'Ascenzo S, Dolo V, Ficorella C, Ricevuto E, Tombolini V. Prostate. 2009 Oct 1;69(14):1529-37.

58. Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy. Napolitano C, Rugghetti A, Landi R, Pinto D, Bellati F, Rahimi H, Spinelli GP, Pauselli S, Sale P, Dolo V, De Lorenzo F, Tomao F, Benedetti-Panici P, Frati L, Nuti M. Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):647-58.

59. Vasculogenic mimicry of human ovarian cancer cells: role of CD147. Millimaggi D, Mari M, D'Ascenzo S, Giusti I, Pavan A, Dolo V. Int J Oncol. 2009 Dec;35(6):1423-8.

60. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V. Cancer Res. 2010 Aug 1;70(15):6150-60.

61. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. Angelucci A, Mari M, Millimaggi D, Giusti I, Carta G, Bologna M, Dolo V. *Gynecol Oncol.* 2010 Dec;119(3):557-63.
62. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, **Dolo V**, Tombolini V, Jannini EA, Festuccia C. *Int J Oncol.* 2012 Mar;40(3):711-20.
63. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Gravina GL, Ranieri G, Muzi P, Marampon F, Mancini A, Di Pasquale B, Di Clemente L, **Dolo V**, D'Alessandro AM, Festuccia C. *Oncol Rep.* 2013 Mar;29(3):1189-95. doi: 10.3892/or.2012.2192. Epub 2012 Dec 18.
64. The effects of platelet gel-released supernatant on human fibroblasts. Giusti I, Rughetti A, D'Ascenzo S, Di Stefano G, Nanni MR, Millimaggi D, Dell'orso L, **Dolo V**. *Wound Repair Regen.* 2013 Mar-Apr;21(2):300-8.
65. Microvesicles as potential ovarian cancer biomarkers. Giusti I, D'Ascenzo S, **Dolo V**. *Biomed Res Int.* 2013;2013:703048.
66. Evaluation of p53 protein as a prognostic factor for oral cancer surgery. Cutilli T, Leocata P, **Dolo V**, Altobelli E. *Br J Oral Maxillofac Surg.* 2013 Dec;51(8):922-7.
67. Topical application of platelet supernatant gel in the management of radiotherapy-induced mucositis: a case report. Di Staso M, Rughetti A, Dell'Orso L, Marampon F, La Verghetta ME, Parente S, Gravina GL, Aielli F, **Dolo V**, Ruggieri V, Franzese P, Bonfili P, Tombolini V, Di Cesare E. *Blood Transfus.* 2014 Jan;12(1):107-10.
68. Extracellular vesicles in prostate cancer: new future clinical strategies? Giusti I, **Dolo V**. *Biomed Res Int.* 2014;2014:561571.
69. Platelet concentration in platelet-rich plasma affects tenocyte behavior in vitro. Giusti I, D'Ascenzo S, Mancò A, Di Stefano G, Di Francesco M, Rughetti A, Dal Mas A, Properzi G, Calvisi V, **Dolo V**. *Biomed Res Int.* 2014;2014:630870.
70. Time-dependent release of extracellular vesicle subpopulations in tumor CABA I cells. Giusti I, Di Francesco M, Cantone L, D'Ascenzo S, Bollati V, Carta G, **Dolo V**. *Oncol Rep.* 2015 Nov;34(5):2752-9.
71. Association between p53 status, human papillomavirus infection, and overall survival in advanced oral cancer after resection and combination systemic treatment. Cutilli T, Leocata P, **Dolo V**, Altobelli E. *Br J Oral Maxillofac Surg.* 2016 Feb;54(2):198-202.
72. The human ovarian cancer cell line CABA I: A peculiar genetic evolution. Giusti I, Cervelli C, D'Ascenzo S, Di Francesco M, Ligas C, D'Alessandro E, Papola F, **Dolo V**. *Int J Mol Med.* 2016 Apr;37(4):879-88.
73. p53 as a prognostic marker associated with the risk of mortality for oral squamous cell carcinoma. Cutilli T, Leocata P, **Dolo V**, Altobelli E. *Oncol Lett.* 2016 Aug;12(2):1046-1050.
74. Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications. Giusti I, Di Francesco M, **Dolo V**. *Curr Cancer Drug Targets.* 2017;17(3):221-235.
75. From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis. Giusti I, Delle Monache S, Di Francesco M, Sanità P, D'Ascenzo S, Gravina GL, Festuccia C, **Dolo V**. *Tumour Biol.* 2016 Sep;37(9):12743-12753.
76. Extracellular Vesicle-Shuttled mRNA in Mesenchymal Stem Cell Communication. Ragni E, Banfi F, Barilani M, Cherubini A, Parazzi V, Larghi P, **Dolo V**, Bollati V, Lazzari L. *Stem Cells.* 2017 Apr;35(4):1093-1105.

